副教授

个人介绍：

姚大红，副教授，硕士生导师，深圳市高层次人才，“润园青年PI”人才，从事人工智能创新药物研发。2008-2018年于沈阳药科大学-四川大学药学专业学习，获药学学士及药物化学博士学位。2018-2020年，分别于哈尔滨医科大学-深圳大学-澳门科技大学进行博士后研究工作，2020年11月加入深圳技术大学药学院。发表SCI论文50余篇，授权专利10余项，获省部级科技进步奖3次。主持包括国家自然科学基金，科技部重大专项子课题，博士后基金，广东省自然科学基金青和深圳市基础研究基金10余项。

科研项目：

1.博士后面上一等，ATAD2抑制剂的设计合成及抗三阴性乳腺癌的机制研究（2019M650213），2019-2020，12万元，主持。

2.科技部重大专项-重大新药创制子课题，中药民族药组分资源库建设（2018ZX09735-005），2019-2021，845.0万元，主持。

3.国家自然科学基金青年项目，双靶向ATAD2/PAK1抗三阴性乳腺癌的小分子抑制剂的设计合成及机制研究（82003580），2021.01-2023.12，24万，主持。

4.广东省基础与应用基础研究青年基金，靶向ATAD2小分子抑制剂设计合成及抗三阴性乳腺癌作用机制研究（2019A1515110482），2020.01-2022.12，10万元，主持。

5.广东省基础与应用基础研究面上基金，双靶向PAK1/CARM1抗BRCA1突变型三阴性乳腺癌的小分子抑制剂的设计及作用机制研究（2024A1515012317），2024.01-2026.12，10万元，主持。

6.深圳市基础研究面上项目，基于结构的靶向ATAD2小分子抑制剂设计合成及抗三阴性乳腺癌作用机制研究（JCYJ20190808171803553），2020.02-2023.02，30万元，主持。

7.深圳市基础研究高校稳定支持计划项目，三阴性乳腺癌中双靶向BRD4/PAK1的小分子抑制剂的设计合成及机制研究（20220717181409001），2022.10-2025.09，19.6万元，主持。

8.国家自然科学基金面上项目，双靶向SIRT3/PAK1抗糖酵解依赖亚型三阴性乳腺癌小分子化合物的设计合成及作用机制研究（82173666），2022.01-2025.12，22万，合作单位主持。

代表成果：

1.Minru Liao^#,Dahong Yao^#, Lifeng Wu^#, Chaodan Luo, Zhiwen Wanga, Jin Zhangc, Bo Liu*. Targeting the Warburg effect: A revisited perspective from molecular mechanisms to traditional and innovative therapeutic strategies in cancer.Acta Pharmaceutica Sinica B. 2024,14(3):953-1008.(中科院1区,Top,IF = 14.5)

2.QianQian Yang^#, Chen Chen^#,Dahong Yao^#, Wei Liu, Bo Liu*, Jin Zhou, Dabo Pan, Cheng Peng, Gu Zhan*, Bo Han*. Catalytic Atroposelective Synthesis of Axially Chiral Azomethine Imines and Neuroprotective Activity Evaluation.Angew Chem Int Ed Engl.2024, 63(5):e202312663.(中科院1区,Top,IF = 16.1)

3.Xi Zhao, Xiaoling Cheng, Zhiying Liu, Weiji Chen, Wenli Hao, Shuangshuang Ma, Jin Zhang*, Wei Huang*,Dahong Yao*.Design, synthesis and biological evaluation of plant-derived miliusol derivatives achieve TNBC profound regression in vivo.Eur J Med Chem.2024,279: 116882.(中科院1区,Top,IF = 6.0)

4.Jiacun Li^#, Ke Zhang^#*, Mei Xu^#, Huanyue Cui, Yaping Guo,Dahong Yao*,

Wenhua Chen, Huaimin Liang, Hangyu Wang, Jinhui Wang*. Baicalin-2-ethoxyethyl ester alleviates renal fibrosis by inhibiting PI3K/AKT/NF-κB signaling pathway.Toxicol Appl Pharmacol.2024, 483:116827. (中科院2区,IF = 3.3).

5.Xuetao Yang^#, Ge Ge^#, Hailin Wang^#, Tianli Liu, Dabo Pan, Xi Zhao, Xiya Chen, Jinhui Wang, Jin Zhang*, Ke Zhang*,Dahong Yao*. Design, synthesis and biological evaluation of novel SIRT3 inhibitors targeting both NAD+ and substrate binding sites for the treatment of acute myeloid leukemia.Eur J Med Chem.2024,276: 116689.(中科院1区,Top,IF = 6.0)

6.Yi Du^#, Xiya Chen^#, Weiji Chen^#, Gang Chen, Xiaoling Cheng, Hailing Wang, Ling Guo, Chenyang Li*,Dahong Yao*. Design, synthesis and biological evaluation of a novel PAK1 degrader for the treatment of triple negative breast cancer.Bioorg Med Chem.2024, 112:117896. (中科院2区,IF = 3.3)

7.Guichan Huang^#, Hailing Wang^#, Xi Zhao, Chen Wang, Jin Zhang,Dahong Yao*, Chenyang Li*. Design, synthesis and biological evaluation of new SIRT3 activators for the treatment of triple-negative breast cancer.Bioorg Med Chem.2024, 118:118040.(中科院2区,IF = 3.3)

8.Wenke Jin^#, Jin Zhang^#, Xiya Chen, Siwen Yin, Haiyang Yu*, Feng Gao*,Dahong Yao*. Unraveling the complexity of histone-arginine methyltransferase CARM1 in cancer: From underlying mechanisms to targeted therapeutics.Biochim Biophys Acta Rev Cancer.2023, 1878:188916. (中科院1区,Top,IF = 9.7)

9.Jiahui Fu^#, Jin Zhang^#, Xiya Chen^#, Zhiying Liu, Xuetao Yang, Zhendan He, Yue Hao*, Bo Liu*,Dahong Yao*.ATPase family AAA domain-containing protein 2(ATAD2): From an epigenetic modulator to cancer therapeutic target.Theranostics.2023, 13(2): 787-809. (中科院1区,Top,IF = 12.4)

10.Jiahui Zhang^#, Jin Zhang^#, Hua Li*, Lixia Chen*,Dahong Yao*. Dual-target inhibitors of PARP1 in cancer therapy: a drug discovery perspective.Drug Discovery Today.2023, 28:1-12. (中科院2区, IF = 6.5)

11.Jin Zhang, Xiya Chen, Gang Chen, Hailing Wang, Lin Jia*, Yue Hao*,Dahong Yao*. Identification of a Novel PAK1/HDAC6 dual inhibitor ZMF-23 that triggers tubulinstathmin regulated cell death in triple negative breast cancer.International Journal of Biological Macromolecules.2023,14:126348(中科院1区, Top, IF = 7.7)

12.Dahong Yao^#, Jieshu You^#, Xuetao Yang, Jin Zhang*, Xiaojun Yao*.Fragment-based design, synthesis and biological evaluation of theophylline derivatives as ATAD2 inhibitors in BT-549 cells.J Enzyme Inhib Med Chem.2023, 38(1):2242601.(中科院2区,IF = 5.6)

13.Xuehai Jia, Ke Zhang*, Shushu Feng, Yuyao Li,Dahong Yao*, Qiaohui Liu, Dong Liu, Xin Li, Jian Huang, Hangyu Wang*, Jinhui Wang. Total glycosides of Rhodiola rosea L. attenuate LPS-induced acute lung injury by inhibiting TLR4/NF-κB pathway.Biomedicine & Pharmacotherapy,2023, 158:114186. (中科院1区,Top,IF = 6.9)

14.Dahong Yao, Jin Jiang, Hualin Zhang, Yelan Huang, Jian Huang*, Jinhui Wang*. Design, synthesis and biological evaluation of dual mTOR/HDAC6 inhibitors in MDA-MB-231 cells.Bioorg Med Chem Lett.2021, 47:128204. (中科院2区,IF = 2.5)

15.Manman Tian^#, Zhenhao Tian^#,Dahong Yao^#, Jing Ning, Sa Deng, Lei Feng*, Xiaokui Huo, Xiangge Tian, Baojing Zhang, Chao Wang, Zhenlong Yu, Xiaochi Ma*.A NIR fluorescent probe for fatty acid amide hydrolase bioimaging and its application in development of inhibitors.J Mater Chem B.2021, 9:6460-6465. (中科院3区,IF = 6.1)

16.Xiangge Tian, Meirong Zhou, Jing Ning, Xiaopeng Deng, Lei Feng, Huilian Huang,Dahong Yao* Xiaochi Ma*. The development of novel cytochrome P450 2J2 (CYP2J2) inhibitor and the underlying interaction between inhibitor and CYP2J2.J ENZYM INHIB MED CH.2021, 36(1):737-748.(中科院2区,IF = 5.6)

17.Dahong Yao^#, Chenyang Li^#, Muhammad Shahid Riaz Rajoka, Zhendan He, Jian Huang, Jinhui Wang*, Jin Zhang*. P21-Activated Kinase 1: Emerging biological functions and potential therapeutic targets in cancer.Theranostics.2020, 10(21):9741-9766. (中科院1区, Top,IF = 12.4).

18.Dahong Yao^#,Ruhan A^#, Jin Jiang, Jian Huang, Jinhui Wang*, Weina Han*. Design, synthesis and biological evaluation of 2-indolinone derivatives as PAK1 inhibitors in MDA-MB-231 cells.Bioorg Med Chem Lett.2020, 30:127355. (中科院2区,IF = 2.5)

19.Dahong Yao^#, Chenyang Li^#, Jin Jiang, Jian huang, Jinhui Wang, Zhendan He*, Jin Zhang*. Design, Synthesis and Biological evaluation of novel HDAC Inhibitors with improved pharmacokinetic profile in breast cancer,Eur J Med Chem.2020, 112648 (中科院1区,Top,IF = 6.0)

20.Dahong Yao, Jin Zhang, Jinhui Wang, Dabo Pan^*, Zhendan He^*. Discovery of novel ATAD2 bromodomain inhibitors that trigger apoptosis and autophagy in breast cells by structure-based virtual screening.J ENZYM INHIB MED CH.2020, 35(1): 713-725.(中科院2区,IF = 5.6)

21.Dahong Yao, Jian huang, Jinhui Wang, Zhendan He*, Jin Zhang*.Design, synthesis and biological evaluation of novel tetrahydrothieno [2,3-c]pyridine substitued benzoyl thiourea derivatives as PAK1 inhibitors in triple negative breast cancer.J ENZYM INHIB MED CH.2020, 35(1): 1524-1538. (中科院2区,IF = 5.6)

22.Dahong Yao, Dabo Pan,Yongqi Zhen, Jian Huang, Jinhui Wang^*, Jin Zhang^*, Zhendan He^*.Ferulin Ctriggerspotent PAK1 and p21-mediated anti-tumor effects in breast cancer by inhibitingTubulin polymerizationin vitroandin vivo.Pharmacol Res.2020, 152:104605. (中科院1区,Top,IF = 9.3)

23.Jin Zhang*, Ling Zou, Pan Tang, Dabo Pan,Zhendan He,Dahong Yao^*.Design, Synthesis and biological evaluation of1H-pyrazolo [3,4-d]pyrimidine derivatives as PAK1 inhibitors that trigger apoptosis, ER stress and anti-migration effect in MDA-MB-231 cells.Eur J Med Chem.2020,112220.(中科院1区,Top,IF = 6.0)

24.Xiaobin Xin^#,Dahong Yao^#, Ke Zhang*, Shuai Han, Danni Liu, Hangyu Wang, Xueying Liu, Guoyu Li, Jian Huang, Jinhui Wang*.Protective effects of Rosavin on bleomycin-induced pulmonary fibrosis via suppressing fibrotic and inflammatory signaling pathways in mice.Biomed Pharmacother,2019, 115:108870. (中科院1区,Top,IF = 6.9)

25.Dahong Yao^#, Jie Liu, Liang Ouyang^*. What structural modifications can be used for BRD4 inhibitors for their use in leukemia therapy?Future Med Chem,2017, 9(9):839-842. (中科院4区,IF = 3.2)

26.Dahong Yao^#, Yuxin Zhou, Linjuan Zhu, Liang Ouyang, Jin Zhang, Yingnan Jiang, Yuqian Zhao, Dejuan Sun, Shilin Yang^*, Yang Yu^*, Jinhui Wang.Design, synthesis and structure-activity relationship studies of a focused library of pyrimidine moiety with anti-proliferative and anti-metastasis activities in triple negative breast cancer,Eur J Med Chem,2017, 140:155-171.(中科院1区,Top,IF = 6.0)

27.Dahong Yao^#, Yinnan Jiang, Suyu Gao, Lei Shang, Yuqian Zhao, Jian Huang, Jinhui Wang^*, Shilin Yang^*, Lixia Chen^*. Deconvoluting the complexity of microRNAs in autophagy to improve potential cancer therapy,Cell Proli,2016, 49(5):541-53. (中科院1区,Top,IF = 5.9)

28.Dahong Yao^#, Jing Wang, Guan Wang, Yinnan Jiang, Lei Shang, Yuqian Zhao, Jian Huang, Shilin Yang^*, Jinhui Wang^*, Yamei Yu^*. Design, synthesis and biological evaluation of coumarin derivatives as novel acetylcholinesterase inhibitors that attenuate H2O2-induced apoptosis in SH-SY5Y cells,Bioorg Chem,2016, 68:112-23. (中科院1区,Top,IF = 4.5)

29.Dahong Yao^#, Peiqi Wang, Jin Zhang, Leilei Fu, Liang Ouyang^*, Jinhui Wang^*. Deconvoluting the relationships between autophagy and metastasis for potential cancer therapy.Apoptosis,2016, 21(6):683-98. (中科院2区,IF = 6.1)

联系方式：

yaodahong@sztu.edu.cn